1.Introduction

The Board of Directors of K-One Technology Bhd (“K-One Tech” or “Company”) is pleased to announce that its wholly owned subsidiary, K-One Industry Sdn. Bhd. (“K-One Ind”) has on 21 January 2020 signed a Development & Manufacturing Agreement (“Agreement”) with a customer to develop and manufacture specific consumer healthcare products.

2.Background of Customer

The customer is US based which specializes in the development and marketing of innovative products designed for promoting healthcare and wellness which are distributed to multifarious countries worldwide under various notable brand names.

3.Scope Of Work

K-One Ind will assist the customer to develop and manufacture one or more of their new commercial products. The concepts, designs, methods, information and manufacturing processes developed by K-One Ind for the customer will belong exclusively to the customer. In this connection, the customer will grant sole manufacturing rights to K-One Ind to manufacture the said product(s) for a minimum of 5 years commencing from the first production batch for the commercial market or end-of-life of the said product(s), for which the termination of manufacturing depends on whichever comes first.

4.Financial Effects

The Agreement does not specify contract volumes or amounts but is based on forecast sales. The current forecasted sales revenue for the initial product(s) to be developed and manufactured is estimated to be RM12 million per year which is expected to contribute positively towards the earnings of the Company for the financial year ending 31 December 2020 and subsequent years based on the above indicated rights to manufacture. The Agreement will not have any effect on the issued and paid-up share capital of the Company.

5.Risk Factors

Risk factors affecting the Agreement include availability of skilled manpower and materials, changes in pricing, market demand volatility, competition and foreign currency rates fluctuation. Notwithstanding, the Company has established a successful track record in undertaking electronics manufacturing services which would help to mitigate such risks.

6.Directors’ And Substantial Shareholders’ Interests

None of the Directors and/or major shareholders of the Company and/or persons connected with them have any direct or indirect interest in the Agreement.

7.Directors’ Statement

The Board is of the opinion that the signing of this Agreement is in the best interest of the Company.

This announcement is dated 22 January 2020.